Syntone Ventures LLC, 10% Owner at Outlook Therapeutics, Inc. (OTLK), bought 3,000,000 shares at $1.00 ($3.0M) on 2021-02-03, disclosed to the SEC on 2021-02-04.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.